Aytu Biopharma (AYTU) Long-Term Deferred Tax (2015 - 2023)

Aytu Biopharma (AYTU) reported Long-Term Deferred Tax of $100000.0 for Q2 2023, down 99.75% quarter-over-quarter from $39.6 million in Q2 2020.

Aytu Biopharma (AYTU) Long-Term Deferred Tax (2015 - 2023) Analysis & Trends

Aytu Biopharma (AYTU) has 5 years of Long-Term Deferred Tax data on file, last reported at $100000.0 in Q2 2023.

Long-Term Deferred Tax for Q2 2023 came in at $100000.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was $100000.0 (changed N/A YoY), and the FY2023 annual result was $100000.0, changed N/A from the prior year.
Long-Term Deferred Tax declined to $100000.0 in Q2 2023 per AYTU's latest filing, from $39.6 million in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $39.6 million in Q2 2020 and troughed at $100000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	Aytu Biopharma	24.60 Mn	-2.12 Mn	7.60 Mn

Download Data